JP2013522236A - レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー - Google Patents

レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー Download PDF

Info

Publication number
JP2013522236A
JP2013522236A JP2012557280A JP2012557280A JP2013522236A JP 2013522236 A JP2013522236 A JP 2013522236A JP 2012557280 A JP2012557280 A JP 2012557280A JP 2012557280 A JP2012557280 A JP 2012557280A JP 2013522236 A JP2013522236 A JP 2013522236A
Authority
JP
Japan
Prior art keywords
cell
biological sample
patient
lymphoma
hodgkin lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012557280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522236A5 (enExample
Inventor
エイチ．スチャフエル ペテル
ズハング リング‐フア
バルトレトト ジェイ．ブラケ
ヘイセ カルラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2013522236A publication Critical patent/JP2013522236A/ja
Publication of JP2013522236A5 publication Critical patent/JP2013522236A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012557280A 2010-03-12 2011-03-11 レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー Pending JP2013522236A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31367010P 2010-03-12 2010-03-12
US61/313,670 2010-03-12
PCT/US2011/028097 WO2011112933A1 (en) 2010-03-12 2011-03-11 Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor

Publications (2)

Publication Number Publication Date
JP2013522236A true JP2013522236A (ja) 2013-06-13
JP2013522236A5 JP2013522236A5 (enExample) 2014-04-24

Family

ID=43799739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012557280A Pending JP2013522236A (ja) 2010-03-12 2011-03-11 レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー

Country Status (11)

Country Link
US (3) US20110223157A1 (enExample)
EP (1) EP2544687A1 (enExample)
JP (1) JP2013522236A (enExample)
KR (1) KR20130038838A (enExample)
CN (1) CN103068386A (enExample)
AR (1) AR080505A1 (enExample)
AU (1) AU2011224166B2 (enExample)
CA (1) CA2792872A1 (enExample)
MX (1) MX2012010367A (enExample)
TW (1) TWI509247B (enExample)
WO (1) WO2011112933A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524478A (ja) * 2012-08-09 2015-08-24 セルジーン コーポレイション ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法
JP2017503481A (ja) * 2013-12-06 2017-02-02 セルジーン コーポレイション 血液癌を治療する方法及び免疫調節療法に対する臨床的感受性の予測因子としてのバイオマーカーの使用
JP2018536387A (ja) * 2015-09-29 2018-12-13 エイチティージー モレキュラー ダイアグノスティクス， インコーポレイテッド びまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）を亜型決定するための方法
JP2019504063A (ja) * 2016-01-08 2019-02-14 セルジーン コーポレイション がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
JP2020143083A (ja) * 2014-05-19 2020-09-10 セルジーン コーポレイション 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120134969A1 (en) 2009-05-25 2012-05-31 Hiroshi Handa Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
CN103688176A (zh) 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
US20150167097A1 (en) 2012-09-20 2015-06-18 Emory University CLASSIFIERS OF NF-kB PATHWAY ACTIVATION, DEVICES, AND METHODS OF USE THEREOF
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
TW201526897A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
JP2016521280A (ja) 2013-05-03 2016-07-21 セルジーン コーポレイション 併用療法を用いて癌を治療する方法
LV14985B (lv) 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process
US20160282354A1 (en) 2013-11-08 2016-09-29 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
JP6640126B2 (ja) 2014-06-27 2020-02-05 セルジーン コーポレイション セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
US11459613B2 (en) 2015-09-11 2022-10-04 The Brigham And Women's Hospital, Inc. Methods of characterizing resistance to modulators of Cereblon
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
EP3484466A1 (en) * 2016-07-13 2019-05-22 Takeda Pharmaceutical Company Limited Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
US20180238886A1 (en) * 2017-01-31 2018-08-23 Celgene Corporation Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
AU2019351811B2 (en) 2018-10-01 2025-01-02 Celgene Corporation Combination therapy for the treatment of cancer
US12400737B2 (en) * 2018-10-10 2025-08-26 Celgene Corporation Methods of classifying diffuse large B-cell lymphoma
WO2025118133A1 (zh) * 2023-12-05 2025-06-12 浙江普洛家园药业有限公司 一种(s)-来那度胺-5-位衍生物及其合成方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528973A (ja) * 2003-05-15 2006-12-28 セルジーン・コーポレーション ３−（４−アミノ−１−オキソ−１，３−ジヒドロイソインドール−２−イル）−ピペリジン−２，６−ジオンの多形相を含む、ガン治療用医薬組成物
WO2008019065A1 (en) * 2006-08-03 2008-02-14 Celgene Corporation Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
WO2009021034A2 (en) * 2007-08-06 2009-02-12 University Of Rochester Methods of treating b-cell cancers
WO2009020590A1 (en) * 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
WO2009075797A2 (en) * 2007-12-07 2009-06-18 Celgene Corporation Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
JP2009191072A (ja) * 2002-05-17 2009-08-27 Celgene Corp 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
EP0456950A1 (en) * 1990-05-16 1991-11-21 CONTRAVES ITALIANA S.p.A. Actuator for restraint/release (R/R) devices, particularly for space applications
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009191072A (ja) * 2002-05-17 2009-08-27 Celgene Corp 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物
JP2006528973A (ja) * 2003-05-15 2006-12-28 セルジーン・コーポレーション ３−（４−アミノ−１−オキソ−１，３−ジヒドロイソインドール−２−イル）−ピペリジン−２，６−ジオンの多形相を含む、ガン治療用医薬組成物
WO2008019065A1 (en) * 2006-08-03 2008-02-14 Celgene Corporation Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
WO2009021034A2 (en) * 2007-08-06 2009-02-12 University Of Rochester Methods of treating b-cell cancers
WO2009020590A1 (en) * 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
WO2009075797A2 (en) * 2007-12-07 2009-06-18 Celgene Corporation Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6015008631; Ｊｏｈｎ　Ｐ．　Ｌｅｏｎａｒｄ　ｅｔ　ａｌ．: 'Ｔａｒｇｅｔｅｄ　Ｔｒｅａｔｅｎｔ　ａｎｄ　Ｎｅｗ　Ａｇｅｎｔｓ　ｉｎ　Ｄｉｆｆｕｓｅ　Ｌａｒｇｅ　Ｂ-Ｃｅｌｌ　Ｌｙｍｐｈｏｍａ' Ｓｅｍｉｎａｒｓ　ｉｎ　ＨＥＭＡＴＯＬＯＧＹ Ｖｏｌ．４５　（ｓｕｐｐｌ　２）, 2008, Ｓ１１-Ｓ１６ *
JPN6015008633; Ｒ．　Ｅｒｉｃ　Ｄａｖｉｓ　ｅｔ　ａｌ．: 'Ｃｏｎｓｔｉｔｕｔｉｖｅ　Ｎｕｃｌｅａｒ　Ｆａｃｔｏｒ　kappaＢ　Ａｃｔｉｖｉｔｙ　Ｉｓ　Ｒｅｑｕｉｒｅｄ　ｆｏｒ　Ｓｕｒｖｉｖａｌ　ｏｆ　Ａｃｔｉｖａｔｅｄ　Ｂ　Ｃｅｌｌ-ｌｉｋｅ　Ｄｉｆｆｕｓｅ　Ｌ' Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．１９４，　Ｎｏ．１２, 20011217, １８６１-１８７４ *
JPN6015008634; Ｌａｕｒａ　Ｐａｓｑｕａｌｕｃｃｉ　ｅｔ　ａｌ．: 'Ｉｎａｃｔｉｖａｔｉｏｎ　ｏｆ　ｔｈｅ　ＰＲＤＭ１／ＢＬＩＭＰ１　ｇｅｎｅ　ｉｎ　ｄｉｆｆｕｓｅ　ｌａｒｇｅ　Ｂ　ｃｅｌｌ　ｌｙｍｐｈｏｍａ' Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．２０３，　Ｎｏ．２, 20060221, ３１１-３１７ *
JPN6015008636; Ｌｅｎｚ　ｅｔ　ａｌ．: 'Ｍｏｌｅｃｕｌａｒ　ｓｕｂｔｙｐｅｓ　ｏｆ　ｄｉｆｆｕｓｅ　ｌａｒｇｅ　Ｂ-ｃｅｌｌ　ｌｙｍｐｈｏｍａ　ａｒｅｓｅ　ｂｙ　ｄｉｓｔｉｎｃｅ　ｇｅｎｅｔｉｃ　ｐａｔｈｗａｙｓ' ＰＮＡＳ Ｖｏｌ．１０５，　Ｎｏ．３６, 20080909, １３５２０-１３５２５ *
JPN6015008639; Ｐ　Ｌ　Ｚｉｎｚａｎｉ　ｅｔ　ａｌ．: 'Ｉｄｅｎｔｉｆｉｃａｔｉｏｎ　ｏｆ　ｏｕｔｃｏｍｅ　ｐｒｅｄｉｃｔｏｒｓ　ｉｎ　ｄｉｆｆｕｓｅ　ｌａｒｇｅ　Ｂ-ｃｅｌｌ　ｌｙｍｐｈｏｍａ．　Ｉｍｍｕｎｏｈｉｓｔｏｃｈｅｍｉｃａｌ　ｐｒｏｆｉｌｉｎｇ' Ｍａｌｉｇｎａｎｔ　Ｌｙｍｐｈｏｍａｓ Ｖｏｌ．９０，　Ｎｏ．３, 2005, ３４１-３４７ *
JPN6015008640; Ｗｉｌｌｉａｍ　Ｗ．Ｌ．　Ｃｈｏｉ　ｅｔ　ａｌ．: 'Ａ　Ｎｅｗ　Ｉｍｍｕｎｏｓｔａｉｎ　Ａｌｇｏｒｉｔｈｍ　Ｃｌａｓｓｉｆｉｅｓ　Ｄｉｆｆｕｓｅ　Ｌａｒｇｅ　Ｂ-Ｃｅｌｌ　Ｌｙｍｐｈｏｍａ　ｉｎｔｏ　Ｍｏｌｅｃｕｌａｒ　Ｓｕｂｔｙｐｅｓ　ｗｉｔｈ　Ｈｉ' Ｃｌｉｎｉｃａｌ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．１５，　Ｎｏ．１７, 20090901, ５４９４-５５０２ *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524478A (ja) * 2012-08-09 2015-08-24 セルジーン コーポレイション ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法
JP2017503481A (ja) * 2013-12-06 2017-02-02 セルジーン コーポレイション 血液癌を治療する方法及び免疫調節療法に対する臨床的感受性の予測因子としてのバイオマーカーの使用
JP2020143083A (ja) * 2014-05-19 2020-09-10 セルジーン コーポレイション 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン
JP2018536387A (ja) * 2015-09-29 2018-12-13 エイチティージー モレキュラー ダイアグノスティクス， インコーポレイテッド びまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）を亜型決定するための方法
US11384399B2 (en) 2015-09-29 2022-07-12 Htg Molecular Diagnostics, Inc. Methods for subtyping diffuse large B-cell lymphoma (DLBCL)
JP2019504063A (ja) * 2016-01-08 2019-02-14 セルジーン コーポレイション がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
JP2021121799A (ja) * 2016-01-08 2021-08-26 セルジーン コーポレイション がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
JP7113942B2 (ja) 2016-01-08 2022-08-05 セルジーン コーポレイション がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
US11460471B2 (en) 2016-01-08 2022-10-04 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
JP2022166014A (ja) * 2016-01-08 2022-11-01 セルジーン コーポレイション がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
US12474342B2 (en) 2016-01-08 2025-11-18 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies

Also Published As

Publication number Publication date
WO2011112933A1 (en) 2011-09-15
TWI509247B (zh) 2015-11-21
AU2011224166A1 (en) 2012-10-04
MX2012010367A (es) 2012-11-23
AU2011224166B2 (en) 2014-08-21
EP2544687A1 (en) 2013-01-16
US20150174114A1 (en) 2015-06-25
US20160008344A1 (en) 2016-01-14
CA2792872A1 (en) 2011-09-15
US20110223157A1 (en) 2011-09-15
TW201135231A (en) 2011-10-16
AR080505A1 (es) 2012-04-11
CN103068386A (zh) 2013-04-24
KR20130038838A (ko) 2013-04-18

Similar Documents

Publication Publication Date Title
JP2013522236A (ja) レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー
TWI653977B (zh) 利用３－（４－（（４－（嗎啉基甲基）苄基）氧基）－１－氧異吲哚啉－２－基）六氫吡啶－２，６－二酮治療癌症之方法
JP6348192B2 (ja) ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法
US12400737B2 (en) Methods of classifying diffuse large B-cell lymphoma
HK1182626A (en) Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
HK40068746A (en) Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
HK1211489B (en) Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151124